CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Gefitinib retreatmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00824746
NCT00824746Phase 2Completed
CompareCT.gov

Retreatment of Gefitinib in the Patients With Non-small Cell Lung Cancer (NSCLC) Previously Responded to Gefitinib A Single Arm, Open Label, Phase II Study

Chonnam National University Hospital·interventional·Posted Jan 19, 2009·Updated Feb 26, 2013

In Brief

A Phase 2 clinical trial evaluating Gefitinib retreatment for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 23 participants across 1 site.

Detailed Summary

A single arm, open label, prospective, phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous gefitinib failure. Primary endpoint * to assess Disease Control Rate (Remission + Stable disease) Secondary endpoints * to assess the progression free survival

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesSouth Korea
CollaboratorsAstraZeneca

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 19, 2009
Enrollment StartJan 1, 2009
Primary CompletionJun 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17.5 years ago

Interventions

Gefitinib retreatmentdrug

phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.